Ascent Group’s Quest Diagnostics DGX Stock Holding History

Ascent Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$374K	Buy	1,767 +2	+0.1%	+$393	0.01%	608
2026 Q1	$346K	Buy	+1,765	New	+$343K	0.01%	583
2025 Q3	–	Sell	-9,498	Closed	-$1.71M	–	750
2025 Q2	$1.71M	Buy	9,498 +213	+2%	+$37K	0.07%	241
2025 Q1	$1.57M	Buy	+9,285	New	+$1.53M	0.07%	262
2022 Q3	–	Sell	-1,812	Closed	-$247K	–	469
2022 Q2	$247K	Buy	+1,812	New	+$247K	0.03%	422
2022 Q1	–	Sell	-4,658	Closed	-$641K	–	446
2021 Q4	$641K	Buy	+4,658	New	+$709K	0.08%	261

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Ascent Group's DGX Position: Q2 2026 in Review

Ascent Group increased its Quest Diagnostics (DGX) stake by 0.11% in Q2 2026, buying an estimated $393 and bringing the position to 1,767 shares worth $374K. The position accounts for 0.01% of the portfolio, ranked #608.

Ascent Group first reported a position in DGX in Q4 2021 and has held it in 6 quarters since. The position peaked at $1.71M in Q2 2025. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Ascent Group held 1,767 shares of Quest Diagnostics worth $374K as of Q2 2026.
Ascent Group bought 2 Quest Diagnostics shares in Q2 2026, an estimated $393.
Quest Diagnostics made up 0.01% of Ascent Group's portfolio in Q2 2026, its #608 holding.
Ascent Group first reported a position in Quest Diagnostics in Q4 2021 and has held it in 6 quarters since.
Ascent Group's Quest Diagnostics position peaked at $1.71M in Q2 2025.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.